Omalizumab vs. Placebo in the management of chronic idiopathic urticaria: A systematic review

World Allergy Organization Journal

Volumn 7, Issue 1, 2014, Pages

  Carrillo, Diana C ^a   Borges, Mario Sanchez ^b   Garcia, Elizabeth ^c   Egea, Eduardo ^d   Serrano, Carlos D ^a  

^a FUNDACIÓN VALLE DEL LILI   (Colombia)

^b Centro Docente la Trinidad   (Venezuela)

^c Allergy Unit   (Colombia)

^d UNIVERSIDAD DEL NORTE   (Colombia)

Author keywords

Angioedema; Antibodies; Humanized; Monoclonal; Urticaria

Indexed keywords

OMALIZUMAB; PLACEBO;

ANGIONEUROTIC EDEMA; ARTHRALGIA; CHRONIC URTICARIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSMENORRHEA; HEADACHE; HUMAN; INJECTION SITE REACTION; INJURY SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; REVIEW; RHINOPHARYNGITIS; SCORING SYSTEM; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

EID: 84988911670     PISSN: None     EISSN: 19394551     Source Type: Journal    
DOI: 10.1186/s40413-014-0050-z     Document Type: Review

References (23)

1. Greaves MW: Chronic urticaria. N Engl J Med 1995, 332(26):1767-72.
2. Gaig P, Olona M, Muioz Lejarazu D, Caballero MT, Dominguez FJ, Echechipia S, Garcia Abujeta JL, Gonzalo MA, Lleonart R, Martinez Cicera C, Rodriguez A, Ferrer M: Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol 2004, 14(3):214-20.
3. Bergstrom KG: Chronic Urticaria: Omalizumab and Review of Therapeutic Options. J Drugs Dermatol 2013, 12(6):715-6.
4. Kulthanan K, Jiamton S, Thumpimukvatana N, Pinkaew S: Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol 2007, 34(5):294-301.
5. Nam YH, Kim JH, Jin HJ, Hwang EK, Shin YS, Ye YM, Park H-S: Effects of omalizumab treatment in patients with refractory chronic urticaria. Allergy Asthma Immunol Res 2012, 4(6):357-61.
6. Saini SS: Chronic Spontaneous Urticaria: Etiology and Pathogenesis. Immunol Allergy Clin North Am 2014, 34(1):33-52.
7. Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A, Bousquet PJ, Bousquet J, Canonica GW, Church MK, Godse KV, Grattan CE, Greaves MW, Hide M, Kalogeromitros D, Kaplan AP, Saini SS, Zhu XJ, Zuberbier T: Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy 2011, 66(3):317-30.
8. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, Church MK, Ensina LF, Giminez-Arnau A, Godse K, Gonialo M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Abdul Latiff AH, Mathelier-Fusade P, Metz M, Saini SS, Sinchez-Borges M, Schmid-Grendelmeier P, Simons FE, Staubach P, Sussman G, Toubi E, Vena GA, Wedi B, Zhu XJ, Nast A, Maurer M: Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2014, 69(7):e1-e29.
9. Francis L, Leiva-Salinas M, Silvestre JF: Omalizumab in the treatment of chronic urticaria. Actas Dermosifiliogr 2014, 105(1):45-52.
10. Lefvre AC, Deleuran M, Vestergaard C: A long term case series study of the effect of omalizumab on chronic spontaneous urticaria. Ann Dermatol 2013, 25(2):242-5.
11. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P: Safety and tolerability of omalizumab. Clin Exp Allergy 2009, 39(6):788-97.
12. Kaplan AP, Popov TA: Biologic agents and the therapy of chronic spontaneous urticaria. Curr Opin Allergy Clin Immunol 2014, 14(4):347-53.
13. Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI)? a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19(3):210-6.
14. Valero A, Herdman M, Bartra J, Ferrer M, Jauregui I, Davila I, del Cuvillo A, Montoro J, Mullol J, Sastre J, Canonica GW, Baiardini I: Adaptation and validation of the Spanish version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL). J Investig Allergol Clin Immunol 2008, 18(6):426-32.
15. Mlynek A, Magerl M, Hanna M, Lhachimi S, Baiardini I, Canonica GW, Brzoza Z, Kasperska-Zajac A, Rogala B, Zalewska-Janowska A, Zuberbier T, Maurer M: The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy 2009, 64(6):927-36.
16. Medical Search Terms Omalizumab [Available from: https://www.dropbox. com/s/8hhaisftmbxx4iy/search-strategy-%283%29%5B1%5D.pdf?dl=0]
17. Higgins J, Green S: Manual Cochrane de revisiones sistemticas de intervenciones. [Available from: http://es.cochrane.org/sites/es.cochrane. org/files/uploads/Manual-Cochrane-510-reduit.pdf]
18. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK: Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008, 122(3):569-73.
19. Maurer M, Rosen K, Hsieh HJ, Saini S, Grattan C, Gimenez-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T: Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl JMed 2013, 368(10):924-35.
20. Maurer M, Altrichter S, Bieber T, Biedermann T, Brautigam M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, Reich K, Ruiff F, Schikel K, Sengupta K, Sieder C, Simon JC, Wedi B, Zuberbier T, Mahler V, Staubach P: Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011, 128(1):202-9. e5.
21. Saini S, Rosen KE, Hsieh H-J, Wong DA, Conner E, Kaplan A, Spector S, Maurer M: A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine? refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011, 128(3):567-73. e1.
22. Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, Veith J, Kamath N, Staubach P, Jakob T, Stirling RG, Kuna P, Berger W, Maurer M, Rosin K: Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013, 132(1):101-9.
23. Saini SS, Bindslev-Jensen C, Maurer M, Grob J-J, Bulbul Baskan E, Bradley MS, Canvin J, Rahmaoui A, Georgiou P, Alpan O, Spector S, Rosin K: Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study. J Invest Dermatol 2014, in press.